https://www.selleckchem.com/pr....oducts/i-bet-762.htm
The overall objective response rate was 73%, the median PFS was 5.7months (95% confidence interval [CI] 3.6-11.8), and the median overall survival was 20.1months (95% CI 13.7-not reached). No statistically significant difference in progression-free survival (PFS) were noted between patients treated with CPT-11 and those treated with AMR. There were no treatment-related deaths in this study. Maintenance therapy with CPT-11 or AMR after induction therapy might be effective in some patients. Maintenance therapy with CPT-11 or AMR after i